HitGen Inc
688222
Company Profile
Business description
HitGen Inc is engaged in drug research and development and provision of technical consultation, technology transfer, and technical services. The company uses DEL technology to provide research and development services for early drug discovery and transfer of new drug R&D projects.
Contact
No. 18, Section 2, Biocity Middle Road
Chengdu Tianfu International Biological City
Shuangliu District, Sichuan Province
Chengdu610093
CHNT: +86 2885197385
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
483
Stocks News & Analysis
stocks
What AI means for US software companies’ moats
We’re no longer certain that software firms will outperform over the next decade, but positive outcomes remain possible for names like Salesforce.
stocks
Lower moat ratings on four ASX shares due to AI
We believe AI weakens the competitive advantage of these companies.
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.60 | 16.90 | -0.19% |
| CAC 40 | 7,825.79 | 220.01 | -2.73% |
| DAX 40 | 23,183.21 | 407.82 | -1.73% |
| Dow JONES (US) | 47,501.55 | 453.19 | -0.95% |
| FTSE 100 | 10,143.99 | 140.76 | -1.37% |
| HKSE | 25,409.32 | 87.98 | 0.35% |
| NASDAQ | 22,387.68 | 361.31 | -1.59% |
| Nikkei 225 | 52,728.72 | 2,892.12 | -5.20% |
| NZX 50 Index | 13,098.83 | 519.06 | -3.81% |
| S&P 500 | 6,740.02 | 90.69 | -1.33% |
| S&P/ASX 200 | 8,599.00 | 3.30 | -0.04% |
| SSE Composite Index | 4,096.60 | 27.59 | -0.67% |